MedPath
Found 15 clinical trials|View Analysis
Sort by:

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3
Not yet recruiting
Conditions
Nasopharyngeal Carcinoma
Interventions
First Posted Date
2024-10-07
Last Posted Date
2024-10-07
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
400
Registration Number
NCT06629597
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Phase 3
Not yet recruiting
Conditions
Small Cell Lung Cancer
Interventions
First Posted Date
2024-09-25
Last Posted Date
2024-11-15
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
438
Registration Number
NCT06612151
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: intravenous (IV) infusion
First Posted Date
2024-06-14
Last Posted Date
2024-07-05
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
252
Registration Number
NCT06459973
Locations
🇨🇳

Jilin Provincial Cancer Hospital, Changchun, Jilin, China

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Phase 2
Recruiting
Conditions
Locally Advanced or Metastatic Breast Cancer
Interventions
Drug: YL202 should be intravenously infused
First Posted Date
2024-06-03
Last Posted Date
2024-11-15
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
180
Registration Number
NCT06439771
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: YL201
First Posted Date
2024-05-01
Last Posted Date
2024-12-06
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
162
Registration Number
NCT06394414
Locations
🇨🇳

Linyi Central Hospital, Linyi, Shandong, China

🇨🇳

Zaozhuang Municipal Hospital, Zaozhuang, Shandong, China

🇨🇳

West China Hospital, Sichuan University, Sichuan, Sichuan, China

and more 27 locations

A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: YL211
First Posted Date
2024-04-25
Last Posted Date
2024-10-14
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
155
Registration Number
NCT06384352
Locations
🇺🇸

University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States

🇺🇸

Sarah Cannon Research Institute (SCRI) at HealthONE, Denver, Colorado, United States

🇺🇸

Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven, North Haven, Connecticut, United States

and more 10 locations

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Phase 2
Recruiting
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
Drug: YL201 for Injection
First Posted Date
2024-02-05
Last Posted Date
2024-10-16
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
100
Registration Number
NCT06241846
Locations
🇨🇳

Peking University First Hospital, Peking, Beijing, China

🇨🇳

Peking University Third Hospital, Peking, Beijing, China

🇨🇳

Hunan Cancer Hospital, Hunan, Changsha, China

and more 21 locations

A Study of YL202 in Selected Patients with Advanced Solid Tumors

Phase 2
Recruiting
Conditions
NSCLC
Locally Advanced or Metastatic Solid Tumors
Breast Cancer
HNSCC
Interventions
Drug: YL202 should be intravenously infused
First Posted Date
2023-10-30
Last Posted Date
2024-11-15
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
200
Registration Number
NCT06107686
Locations
🇨🇳

The first affiliated hospital of Anhui Medical University, Hefei, Anhui, China

🇨🇳

SiChuan Cancer Hospital, Chengdu, Sichuan, China

🇨🇳

Anhui Tumour Hospital, Hefei, Anhui, China

and more 77 locations

A Study YL201 in Patients With Selected Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Interventions
Drug: YL201 for Injection
First Posted Date
2023-09-28
Last Posted Date
2023-12-20
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
640
Registration Number
NCT06057922
Locations
🇨🇳

Jiangmen Central Hospital, Jiangmen, Guangdong, China

🇨🇳

Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China

🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

and more 52 locations

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Phase 1
Recruiting
Conditions
Non Small Cell Lung Cancer
Breast Cancer
Interventions
Drug: YL202
First Posted Date
2022-12-16
Last Posted Date
2024-11-15
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
80
Registration Number
NCT05653752
Locations
🇺🇸

BRCR Global, Plantation, Florida, United States

🇺🇸

UT health east Texas HOPE Cancer Center, Tyler, Texas, United States

🇺🇸

Summit Cancer Center, Spokane Valley, Washington, United States

and more 10 locations
© Copyright 2025. All Rights Reserved by MedPath